These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
199 related articles for article (PubMed ID: 18281730)
41. Extended-release paliperidone: efficacy, safety and tolerability profile of a new atypical antipsychotic. Owen RT Drugs Today (Barc); 2007 Apr; 43(4):249-58. PubMed ID: 17460786 [TBL] [Abstract][Full Text] [Related]
42. Improvement of oral dyskinesia after switching from aripiprazole to paliperidone: a case report. Lai CH J Neuropsychiatry Clin Neurosci; 2011; 23(3):E18. PubMed ID: 21948908 [No Abstract] [Full Text] [Related]
43. A comparison of continuous subcutaneous paliperidone infusion and repeated subcutaneous injection of risperidone free-base in rats. Marchese G; Pittau B; Casu G; Peddio G; Spada GP; Pira M; Deriu A; Portesani F; Pisu C; Lazzari P; Pani L Eur Psychiatry; 2010 Mar; 25(2):92-100. PubMed ID: 19640686 [TBL] [Abstract][Full Text] [Related]
44. Successful use of paliperidone in a clozapine-resistant schizophrenic patient. Hsieh TH; Liu CT J Neuropsychiatry Clin Neurosci; 2013; 25(2):E36. PubMed ID: 23686056 [No Abstract] [Full Text] [Related]
46. Manic symptoms during a switch from risperidone to paliperidone: a case report. Yang FW; Liang CS J Neuropsychiatry Clin Neurosci; 2011; 23(3):E29. PubMed ID: 21948917 [No Abstract] [Full Text] [Related]
47. The influence of switching from risperidone to paliperidone on the extrapyramidal symptoms and cognitive function in elderly patients with schizophrenia: a preliminary open-label trial. Suzuki H; Gen K; Inoue Y; Hibino H; Mikami A; Matsumoto H; Mikami K Int J Psychiatry Clin Pract; 2014 Jan; 18(1):58-62. PubMed ID: 24047427 [TBL] [Abstract][Full Text] [Related]
48. Paliperidone: a new extended-release oral atypical antipsychotic. Dlugosz H; Nasrallah HA Expert Opin Pharmacother; 2007 Oct; 8(14):2307-13. PubMed ID: 17927485 [TBL] [Abstract][Full Text] [Related]
49. Paliperidone palmitate long-acting injection--prospective year-long follow-up of use in clinical practice. Attard A; Olofinjana O; Cornelius V; Curtis V; Taylor D Acta Psychiatr Scand; 2014 Jul; 130(1):46-51. PubMed ID: 24117209 [TBL] [Abstract][Full Text] [Related]
50. Medication satisfaction in schizophrenia: a blinded-initiation study of paliperidone extended release in patients suboptimally responsive to risperidone. Canuso CM; Grinspan A; Kalali A; Damaraju CV; Merriman U; Alphs L; Awad AG Int Clin Psychopharmacol; 2010 May; 25(3):155-64. PubMed ID: 20216424 [TBL] [Abstract][Full Text] [Related]
51. Risk of arrest in persons with schizophrenia and bipolar disorder in a Florida Medicaid program: the role of atypical antipsychotics, conventional neuroleptics, and routine outpatient behavioral health services. Van Dorn RA; Andel R; Boaz TL; Desmarais SL; Chandler K; Becker MA; Howe A J Clin Psychiatry; 2011 Apr; 72(4):502-8. PubMed ID: 21527125 [TBL] [Abstract][Full Text] [Related]
52. Oral paliperidone extended-release: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability. Citrome L Expert Opin Drug Metab Toxicol; 2012 Jul; 8(7):873-88. PubMed ID: 22632481 [TBL] [Abstract][Full Text] [Related]
54. Using paliperidone as a monotherapeutic agent on a schizophrenic patient with cirrhosis of the liver. Chou HW; Chen CL J Neuropsychiatry Clin Neurosci; 2013; 25(1):E37. PubMed ID: 23487226 [No Abstract] [Full Text] [Related]
55. Paliperidone extended-release: safety and tolerability from a metabolic profile perspective. RodrÃguez-MartÃnez A; Quilo CG Clin Drug Investig; 2013 Dec; 33(12):867-76. PubMed ID: 24241935 [TBL] [Abstract][Full Text] [Related]
56. [Possibilities of the treatment of exacerbations of schizophrenia with the long acting atypical antipsychotic paliperidone palmitate]. Morozova MA Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(2):85-8. PubMed ID: 22712069 [No Abstract] [Full Text] [Related]